A Study of LY3200882 in Participants With Solid Tumors (NCT02937272)

🧪 Interventions in This Study

• LY3200882 (DRUG)
• LY3300054 (DRUG)
• Gemcitabine (DRUG)
• nab-Paclitaxel (DRUG)
• Cisplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (18 Sites)

• University of Louisville — Louisville, Kentucky
• Weill Cornell Medical College — New York, New York
• University of Texas MD Anderson Cancer Center — Houston, Texas
• Calvary Mater Newcastle — Newcastle, New South Wales
• St Vincent's Hospital Sydney — Sydney, New South Wales
• Greenslopes Private Hospital — Greenslopes, Queensland
• Princess Margaret Hospital (Ontario) — Lai Chi Kok, Kowloon
• Hopital Saint-Louis — Paris, Cedex 10
• CHRU de Lille — Lille,
• Gustave Roussy — Villejuif,
• Universitätsklinikum Würzburg A. ö. R. — Würzburg, Bavaria
• Charité Campus Virchow-Klinikum — Berlin,
• Istituto Clinico Humanitas — Rozzano, Milano
• Ospedale Policlinico Giambattista Rossi, Borgo Roma — Verona,
• National Cancer Center Hospital — Chuo-Ku, Tokyo
• Hospital Universitari Vall d'Hebron — Barcelona,
• Hospital Universitario 12 de Octubre — Madrid,
• Hospital Clínico Universitario de Valencia — Valencia,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor

• A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
• A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
• A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
• A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
• Concurrent Azeliragon With Craniospinal Irradiation — New York, New York

Explore by condition: All Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.